Loading
A small early trial in which ten people with melanoma that had spread were given copies of their own T cells grown to recognise melanoma proteins. The cells lasted in the body, went to the tumours and shrank some of them, with no serious side effects.
A phase I study of autologous CD8+ T-cell clones against the melanoma antigens MART-1/Melan-A and gp100 in metastatic melanoma: 43 infusions were given to 10 patients, the first without IL-2 and later ones with low-dose IL-2 (PNAS 2002). The clones persisted in response to low-dose IL-2, localised preferentially to tumour sites and eliminated antigen-positive tumour cells (PNAS 2002).
It showed that T cells taken from a patient's blood, selected for one melanoma antigen and grown as clones, can survive after infusion, reach tumours and kill the antigen-carrying cells there.
Shares Endogenous T-cell therapy, Proceedings of the National Academy of Sciences, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/